Trial Profile

The effect of semaglutide in subjects with non-cirrhotic non-alcoholic steatohepatitis

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 23 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

28 Oct 2025 According to a Novo Nordisk media release, secondary analysis from this study will be presented in an Oral presentation (0010) and Efficacy response in subgroups will be presented in a poster (4042) on 10 November at the 76th Annual American Association for the Study of Liver Diseases (AASLD) congress, The Liver Meeting 2025, from 7 to 11 November in Washington D.C., U.S.
07 May 2025 According to a Novo Nordisk media release, once-weekly semaglutide 2.4 mg in MASH was submitted for regulatory approval in both the EU and US, and granted priority review in the US.
06 May 2025 According to a Novo Nordisk media release, data form this trial will be presented at the ECO 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com